Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Higher sales of reagents for fecal occult blood testing and tuberculosis genetic testing for overseas markets, and domestic medical equipment; the prior-year interim period's one-off patent royalty income and changes in the sales mix; the prior-year interim period's one-off extraordinary gain from the transfer of an equity interest in a consolidated subsidiary
There are no applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | 21,388 million yen (YoY +4.7%) |
| Operating profit | 1,587 million yen (YoY -8.2%) |
| Ordinary income | 1,616 million yen (YoY -6.6%) |
| Profit attributable to owners of the parent | 1,125 million yen (YoY -62.2%) |
| Net income per share | ¥34.10 |
| Equity ratio | End of the current fiscal period 69.1 / End of previous period 70.1 |
| Total assets | 64,023 million yen |
| Net assets | 44,247 million yen |
| Full-year earnings forecast | Net Sales 42,000 million yen (YoY +0.2%) / Operating profit 3,070 million yen (YoY +5.2%) / Ordinary income 2,900 million yen (YoY +2.0%) / Net income 2,070 million yen (YoY -44.2%) |
| Annual Dividend Forecast | 58 yen → 58 yen（0.0%） |
| Regional sales | Overseas 6,137 million yen (YoY +12.6%) |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets 1 million yen / Extraordinary loss Loss on disposal and sale of non-current assets 0 million yen |
| Disclosure regarding the going concern assumption | There are no applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None applicable |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for analysts and institutional investors) |
| Issued Shares at Period-End | 34,541,438 |
| Treasury Shares at Period-End | 1,485,822 |
| Factors Behind Changes in Business Performance | Higher sales of reagents for fecal occult blood testing and tuberculosis genetic testing for overseas markets, and domestic medical equipment; the prior-year interim period's one-off patent royalty income and changes in the sales mix; the prior-year interim period's one-off extraordinary gain from the transfer of an equity interest in a consolidated subsidiary |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to higher sales of reagents for fecal occult blood testing and tuberculosis genetic testing for overseas markets, as well as domestic medical equipment. Operating income and ordinary income declined due to the impact of the prior-year interim period's one-off patent royalty income and changes in the sales mix. Interim net income attributable to owners of the parent declined due to the reversal of the prior-year one-off extraordinary gain from the transfer of an equity interest in a consolidated subsidiary.